Traphagen Investment Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.38M | Sell |
9,472
-139
| -1% | -$29.9K | 0.17% | 49 |
|
|
2026
Q1 | $2.09M | Sell |
9,611
-40
| -0.4% | -$8.87K | 0.17% | 52 |
|
|
2025
Q4 | $2.21M | Buy |
9,651
+15
| +0.2% | +$3.42K | 0.18% | 46 |
|
|
2025
Q3 | $2.23M | Buy |
9,636
+10
| +0.1% | +$2.04K | 0.19% | 44 |
|
|
2025
Q2 | $1.79M | Sell |
9,626
-9
| -0.1% | -$1.67K | 0.17% | 50 |
|
|
2025
Q1 | $2.02M | Sell |
9,635
-64
| -0.7% | -$12.4K | 0.21% | 45 |
|
|
2024
Q4 | $1.72M | Buy |
9,699
+5
| +0.1% | +$919 | 0.18% | 46 |
|
|
2024
Q3 | $1.91M | Sell |
9,694
-69
| -0.7% | -$12.9K | 0.19% | 41 |
|
|
2024
Q2 | $1.67M | Sell |
9,763
-60
| -0.6% | -$9.94K | 0.18% | 48 |
|
|
2024
Q1 | $1.79M | Buy |
9,823
+98
| +1% | +$16.9K | 0.19% | 47 |
|
|
2023
Q4 | $1.51M | Sell |
9,725
-103
| -1% | -$15K | 0.18% | 48 |
|
|
2023
Q3 | $1.47M | Buy |
9,828
+5
| +0.1% | +$734 | 0.19% | 41 |
|
|
2023
Q2 | $1.32M | Buy |
9,823
+5,071
| +107% | +$744K | 0.17% | 50 |
|
|
2023
Q1 | $757K | Buy |
4,752
+287
| +6% | +$43.9K | 0.11% | 66 |
|
|
2022
Q4 | $722K | Buy |
4,465
+1,032
| +30% | +$158K | 0.11% | 64 |
|
|
2022
Q3 | $799K | Hold |
3,433
| – | – | 0.15% | 49 |
|
|
2022
Q2 | $826K | Hold |
3,433
| – | – | 0.15% | 48 |
|
|
2022
Q1 | $858K | Sell |
3,433
-2,499
| -42% | -$363K | 0.14% | 48 |
|
|
2021
Q4 | $803K | Buy |
5,932
+63
| +1% | +$7.44K | 0.13% | 57 |
|
|
2021
Q3 | $633K | Buy |
5,869
+40
| +0.7% | +$4.57K | 0.11% | 58 |
|
|
2021
Q2 | $657K | Buy |
5,829
+288
| +5% | +$32.4K | 0.11% | 60 |
|
|
2021
Q1 | $600K | Buy |
5,541
+4
| +0.1% | +$428 | 0.11% | 66 |
|
|
2020
Q4 | $593K | Sell |
5,537
-58
| -1% | -$5.57K | 0.11% | 69 |
|
|
2020
Q3 | $490K | Buy |
5,595
+392
| +8% | +$36.9K | 0.1% | 70 |
|
|
2020
Q2 | $511K | Buy |
5,203
+51
| +1% | +$4.49K | 0.12% | 68 |
|
|
2020
Q1 | $393K | Buy |
5,152
+95
| +2% | +$8.09K | 0.11% | 78 |
|
|
2019
Q4 | $448K | Hold |
5,057
| – | – | 0.11% | 76 |
|
|
2019
Q3 | $383K | Sell |
5,057
-152
| -3% | -$10.4K | 0.1% | 77 |
|
|
2019
Q2 | $379K | Buy |
5,209
+2
| +0% | +$157 | 0.1% | 78 |
|
|
2019
Q1 | $420K | Buy |
+5,207
| New | +$426K | 0.12% | 65 |
|
Other funds holding ABBV
Traphagen Investment Advisors's ABBV Position: Q2 2026 in Review
Traphagen Investment Advisors reduced its AbbVie (ABBV) stake by 1.4% in Q2 2026, selling an estimated $29.9K and leaving 9,472 shares worth $2.38M. The position accounts for 0.17% of the portfolio, ranked #49.
Traphagen Investment Advisors first reported a position in ABBV in Q1 2019 and has held it in 30 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Traphagen Investment Advisors held 9,472 shares of AbbVie worth $2.38M as of Q2 2026.
- Traphagen Investment Advisors sold 139 AbbVie shares in Q2 2026, an estimated $29.9K.
- AbbVie made up 0.17% of Traphagen Investment Advisors's portfolio in Q2 2026, its #49 holding.
- Traphagen Investment Advisors first reported a position in AbbVie in Q1 2019 and has held it in 30 quarters since.
- 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Traphagen Investment Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.